{"id":16,"date":"2025-04-14T14:43:26","date_gmt":"2025-04-14T14:43:26","guid":{"rendered":"https:\/\/e-multipurpose8.ziptemplates.top\/?page_id=16"},"modified":"2026-10-12T12:46:05","modified_gmt":"2026-10-12T10:46:05","slug":"insights","status":"publish","type":"page","link":"http:\/\/5mn.ch\/de\/insights\/","title":{"rendered":"Insights"},"content":{"rendered":"<div data-elementor-type=\"wp-page\" data-elementor-id=\"16\" class=\"elementor elementor-16\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-12a6206 e-flex e-con-boxed e-con e-parent\" data-id=\"12a6206\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6eec687 elementor-widget elementor-widget-text-editor\" data-id=\"6eec687\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\n<h2 class=\"wp-block-heading\">Ihr Daily Brief<\/h2>\n\n\n\n<p class=\"has-text-align-center wp-block-paragraph\">Biotech-News aus der Schweiz und Europa, an jedem Werktag.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"\/de\/#subscribe\">Per E-Mail erhalten<\/a><\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-query db-cards is-layout-flow wp-block-query-is-layout-flow\"><ul class=\"wp-block-post-template is-layout-flow wp-block-post-template-is-layout-flow\"><li class=\"wp-block-post post-1631 post type-post status-publish format-standard has-post-thumbnail hentry category-daily-brief tag-biontech tag-denmark tag-evotec tag-germany tag-lonza tag-oncopeptides tag-switzerland tag-zealand-pharma\">\n\n<figure class=\"wp-block-post-featured-image\"><a href=\"http:\/\/5mn.ch\/de\/insights\/2026\/10\/14\/daily-brief-2026-10-14\/\" target=\"_self\" ><img fetchpriority=\"high\" decoding=\"async\" width=\"1600\" height=\"900\" src=\"http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-14.jpg\" class=\"attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"Lonza, BioNTech, Evotec, Zealand Pharma, Oncopeptides\" style=\"object-fit:cover;\" srcset=\"http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-14.jpg 1600w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-14-300x169.jpg 300w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-14-1024x576.jpg 1024w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-14-768x432.jpg 768w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-14-1536x864.jpg 1536w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-14-18x10.jpg 18w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/><\/a><\/figure>\n\n<div class=\"wp-block-post-date\"><time datetime=\"2026-10-14T08:07:35+02:00\">14\/10\/2026<\/time><\/div>\n\n<h2 class=\"wp-block-post-title\"><a href=\"http:\/\/5mn.ch\/de\/insights\/2026\/10\/14\/daily-brief-2026-10-14\/\" target=\"_self\" >Lonza, BioNTech, Evotec, Zealand Pharma, Oncopeptides<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Lonza: higher profitability targets at its Capital Markets Day; BioNTech: BNT113 misses on progression-free survival, trial continues for overall survival; Evotec: nine-month figures above expectations, guidance confirmed; Zealand Pharma: AI protein deal with Generate Biomedicines; Oncopeptides: SEK 100M share issue for its glioblastoma programme. <\/p><\/div>\n\n<div class=\"taxonomy-post_tag wp-block-post-terms\"><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/biontech\/\" rel=\"tag\">BioNTech<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/denmark\/\" rel=\"tag\">Denmark<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/evotec\/\" rel=\"tag\">Evotec<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/germany\/\" rel=\"tag\">Deutschland<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/lonza\/\" rel=\"tag\">Lonza<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/oncopeptides\/\" rel=\"tag\">Oncopeptides<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/switzerland\/\" rel=\"tag\">Schweiz<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/zealand-pharma\/\" rel=\"tag\">Zealand Pharma<\/a><\/div><\/li><li class=\"wp-block-post post-1606 post type-post status-publish format-standard has-post-thumbnail hentry category-daily-brief tag-formycon tag-polypeptide tag-switzerland\">\n\n<figure class=\"wp-block-post-featured-image\"><a href=\"http:\/\/5mn.ch\/de\/insights\/2026\/10\/13\/daily-brief-2026-10-13\/\" target=\"_self\" ><img decoding=\"async\" width=\"1600\" height=\"900\" src=\"http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-13.jpg\" class=\"attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"PolyPeptide, Formycon\" style=\"object-fit:cover;\" srcset=\"http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-13.jpg 1600w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-13-300x169.jpg 300w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-13-1024x576.jpg 1024w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-13-768x432.jpg 768w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-13-1536x864.jpg 1536w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-13-18x10.jpg 18w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/><\/a><\/figure>\n\n<div class=\"wp-block-post-date\"><time datetime=\"2026-10-13T07:50:39+02:00\">13\/10\/2026<\/time><\/div>\n\n<h2 class=\"wp-block-post-title\"><a href=\"http:\/\/5mn.ch\/de\/insights\/2026\/10\/13\/daily-brief-2026-10-13\/\" target=\"_self\" >PolyPeptide, Formycon<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">PolyPeptide: Samsung Biologics\u2019 takeover offer clears its acceptance threshold; Formycon: FDA accepts the filing for Keytruda biosimilar FYB206. <\/p><\/div>\n\n<div class=\"taxonomy-post_tag wp-block-post-terms\"><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/formycon\/\" rel=\"tag\">Formycon<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/polypeptide\/\" rel=\"tag\">PolyPeptide<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/switzerland\/\" rel=\"tag\">Schweiz<\/a><\/div><\/li><li class=\"wp-block-post post-1559 post type-post status-publish format-standard has-post-thumbnail hentry category-daily-brief tag-ascelia-pharma tag-france tag-idorsia tag-medincell tag-sweden\">\n\n<figure class=\"wp-block-post-featured-image\"><a href=\"http:\/\/5mn.ch\/de\/insights\/2026\/10\/12\/daily-brief-2026-10-12\/\" target=\"_self\" ><img decoding=\"async\" width=\"1600\" height=\"900\" src=\"http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-12.jpg\" class=\"attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"Idorsia, Medincell, Ascelia Pharma\" style=\"object-fit:cover;\" srcset=\"http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-12.jpg 1600w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-12-300x169.jpg 300w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-12-1024x576.jpg 1024w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-12-768x432.jpg 768w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-12-1536x864.jpg 1536w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-12-18x10.jpg 18w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/><\/a><\/figure>\n\n<div class=\"wp-block-post-date\"><time datetime=\"2026-10-12T07:49:25+02:00\">12\/10\/2026<\/time><\/div>\n\n<h2 class=\"wp-block-post-title\"><a href=\"http:\/\/5mn.ch\/de\/insights\/2026\/10\/12\/daily-brief-2026-10-12\/\" target=\"_self\" >Idorsia, Medincell, Ascelia Pharma<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Idorsia: post hoc aprocitentan data at AHA Hypertension; Medincell: FDA approves Weltruza; Ascelia Pharma: Orviglance path after its FDA Type A meeting. <\/p><\/div>\n\n<div class=\"taxonomy-post_tag wp-block-post-terms\"><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/ascelia-pharma\/\" rel=\"tag\">Ascelia Pharma<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/france\/\" rel=\"tag\">Frankreich<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/idorsia\/\" rel=\"tag\">Idorsia<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/medincell\/\" rel=\"tag\">Medincell<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/sweden\/\" rel=\"tag\">Sweden<\/a><\/div><\/li><li class=\"wp-block-post post-1495 post type-post status-publish format-standard has-post-thumbnail hentry category-daily-brief tag-adc-therapeutics tag-gensight-biologics tag-pharvaris\">\n\n<figure class=\"wp-block-post-featured-image\"><a href=\"http:\/\/5mn.ch\/de\/insights\/2026\/10\/09\/daily-brief-2026-10-09\/\" target=\"_self\" ><img loading=\"lazy\" decoding=\"async\" width=\"1600\" height=\"900\" src=\"http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-09.jpg\" class=\"attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"ADC Therapeutics raises $86.6M and resets its debt\" style=\"object-fit:cover;\" srcset=\"http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-09.jpg 1600w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-09-300x169.jpg 300w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-09-1024x576.jpg 1024w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-09-768x432.jpg 768w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-09-1536x864.jpg 1536w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-09-18x10.jpg 18w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/><\/a><\/figure>\n\n<div class=\"wp-block-post-date\"><time datetime=\"2026-10-09T13:14:00+02:00\">09\/10\/2026<\/time><\/div>\n\n<h2 class=\"wp-block-post-title\"><a href=\"http:\/\/5mn.ch\/de\/insights\/2026\/10\/09\/daily-brief-2026-10-09\/\" target=\"_self\" >ADC Therapeutics raises $86.6M and resets its debt<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Also: GenSight\u2019s GS030 optogenetics trial in NEJM and a \u20ac1.0M raise; Pharvaris\u2019 RAPIDe-3 HAE data in The Lancet. <\/p><\/div>\n\n<div class=\"taxonomy-post_tag wp-block-post-terms\"><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/adc-therapeutics\/\" rel=\"tag\">ADC Therapeutics<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/gensight-biologics\/\" rel=\"tag\">GenSight Biologics<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/pharvaris\/\" rel=\"tag\">Pharvaris<\/a><\/div><\/li><li class=\"wp-block-post post-1430 post type-post status-publish format-standard has-post-thumbnail hentry category-daily-brief tag-argenx tag-bavarian-nordic tag-newron tag-valneva tag-zealand-pharma\">\n\n<figure class=\"wp-block-post-featured-image\"><a href=\"http:\/\/5mn.ch\/de\/insights\/2026\/10\/08\/daily-brief-2026-10-08\/\" target=\"_self\" ><img loading=\"lazy\" decoding=\"async\" width=\"1600\" height=\"900\" src=\"http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-08.jpg\" class=\"attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"Argenx halts efgartigimod Phase 3 in Sj\u00f6gren&#8217;s\" style=\"object-fit:cover;\" srcset=\"http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-08.jpg 1600w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-08-300x169.jpg 300w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-08-1024x576.jpg 1024w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-08-768x432.jpg 768w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-08-1536x864.jpg 1536w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-08-18x10.jpg 18w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/><\/a><\/figure>\n\n<div class=\"wp-block-post-date\"><time datetime=\"2026-10-08T07:02:36+02:00\">08\/10\/2026<\/time><\/div>\n\n<h2 class=\"wp-block-post-title\"><a href=\"http:\/\/5mn.ch\/de\/insights\/2026\/10\/08\/daily-brief-2026-10-08\/\" target=\"_self\" >Argenx halts efgartigimod Phase 3 in Sj\u00f6gren&#8217;s<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">FDA keeps Newron hold, Zealand's petrelintide Phase 2 win, Bavarian Nordic lifts guidance, UK pulls Valneva's IXCHIQ. <\/p><\/div>\n\n<div class=\"taxonomy-post_tag wp-block-post-terms\"><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/argenx\/\" rel=\"tag\">argenx<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/bavarian-nordic\/\" rel=\"tag\">Bavarian Nordic<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/newron\/\" rel=\"tag\">Newron<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/valneva\/\" rel=\"tag\">Valneva<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/zealand-pharma\/\" rel=\"tag\">Zealand Pharma<\/a><\/div><\/li><li class=\"wp-block-post post-1379 post type-post status-publish format-standard has-post-thumbnail hentry category-daily-brief tag-abionyx tag-alvotech tag-ascendis-pharma tag-bridgebio tag-forbion tag-lundbeck\">\n\n<figure class=\"wp-block-post-featured-image\"><a href=\"http:\/\/5mn.ch\/de\/insights\/2026\/10\/07\/daily-brief-2026-10-07\/\" target=\"_self\" ><img loading=\"lazy\" decoding=\"async\" width=\"1600\" height=\"900\" src=\"http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-07.jpg\" class=\"attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"Alvotech adds US capacity with LOTTE Biologics\" style=\"object-fit:cover;\" srcset=\"http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-07.jpg 1600w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-07-300x169.jpg 300w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-07-1024x576.jpg 1024w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-07-768x432.jpg 768w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-07-1536x864.jpg 1536w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-07-18x10.jpg 18w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/><\/a><\/figure>\n\n<div class=\"wp-block-post-date\"><time datetime=\"2026-10-07T06:53:47+02:00\">07\/10\/2026<\/time><\/div>\n\n<h2 class=\"wp-block-post-title\"><a href=\"http:\/\/5mn.ch\/de\/insights\/2026\/10\/07\/daily-brief-2026-10-07\/\" target=\"_self\" >Alvotech adds US capacity with LOTTE Biologics<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Also: BridgeBio priority review, a rival to Ascendis; Lundbeck Parkinson's data; Forbion's \u20ac2.3bn funds; Alzinova rights issue. <\/p><\/div>\n\n<div class=\"taxonomy-post_tag wp-block-post-terms\"><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/abionyx\/\" rel=\"tag\">Abionyx<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/alvotech\/\" rel=\"tag\">Alvotech<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/ascendis-pharma\/\" rel=\"tag\">Ascendis Pharma<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/bridgebio\/\" rel=\"tag\">BridgeBio<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/forbion\/\" rel=\"tag\">Forbion<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/lundbeck\/\" rel=\"tag\">Lundbeck<\/a><\/div><\/li><li class=\"wp-block-post post-1319 post type-post status-publish format-standard has-post-thumbnail hentry category-daily-brief tag-alentis tag-alvotech tag-genmab tag-idorsia tag-switzerland\">\n\n<figure class=\"wp-block-post-featured-image\"><a href=\"http:\/\/5mn.ch\/de\/insights\/2026\/10\/06\/daily-brief-2026-10-06\/\" target=\"_self\" ><img loading=\"lazy\" decoding=\"async\" width=\"1600\" height=\"900\" src=\"http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-06.jpg\" class=\"attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"Genmab&#8217;s epcoritamab succeeds in frontline DLBCL\" style=\"object-fit:cover;\" srcset=\"http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-06.jpg 1600w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-06-300x169.jpg 300w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-06-1024x576.jpg 1024w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-06-768x432.jpg 768w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-06-1536x864.jpg 1536w, http:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/daily-brief-2026-10-06-18x10.jpg 18w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/><\/a><\/figure>\n\n<div class=\"wp-block-post-date\"><time datetime=\"2026-10-06T09:11:36+02:00\">06\/10\/2026<\/time><\/div>\n\n<h2 class=\"wp-block-post-title\"><a href=\"http:\/\/5mn.ch\/de\/insights\/2026\/10\/06\/daily-brief-2026-10-06\/\" target=\"_self\" >Genmab&#8217;s epcoritamab succeeds in frontline DLBCL<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Also: Alvotech's FDA capacity win, CSL\u2013Alentis deal worth up to $1.6bn, new Idorsia data at AHA. <\/p><\/div>\n\n<div class=\"taxonomy-post_tag wp-block-post-terms\"><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/alentis\/\" rel=\"tag\">Alentis<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/alvotech\/\" rel=\"tag\">Alvotech<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/genmab\/\" rel=\"tag\">Genmab<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/idorsia\/\" rel=\"tag\">Idorsia<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"http:\/\/5mn.ch\/de\/insights\/tag\/switzerland\/\" rel=\"tag\">Schweiz<\/a><\/div><\/li><\/ul>\n\n\n\n<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Your Daily Brief Swiss and European biotech news, every weekday.<\/p>","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"","ast-site-content-layout":"normal-width-container","site-content-style":"unboxed","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"disabled","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-16","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Insights - 5mn<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/5mn.ch\/de\/insights\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insights - 5mn\" \/>\n<meta property=\"og:description\" content=\"Your Daily Brief Swiss and European biotech news, every weekday.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/5mn.ch\/de\/insights\/\" \/>\n<meta property=\"og:site_name\" content=\"5mn\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-12T10:46:05+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/5mn.ch\\\/insights\\\/\",\"url\":\"https:\\\/\\\/5mn.ch\\\/insights\\\/\",\"name\":\"Insights - 5mn\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/5mn.ch\\\/#website\"},\"datePublished\":\"2025-04-14T14:43:26+00:00\",\"dateModified\":\"2026-10-12T10:46:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/5mn.ch\\\/insights\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/5mn.ch\\\/insights\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/5mn.ch\\\/insights\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"http:\\\/\\\/5mn.ch\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insights\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/5mn.ch\\\/#website\",\"url\":\"https:\\\/\\\/5mn.ch\\\/\",\"name\":\"5mn\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/5mn.ch\\\/#organization\"},\"alternateName\":\"5mn.ch\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/5mn.ch\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/5mn.ch\\\/#organization\",\"name\":\"5mn\",\"alternateName\":\"5mn.ch\",\"url\":\"https:\\\/\\\/5mn.ch\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/5mn.ch\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/5mn.ch\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/5mn-icon-512_1.png\",\"contentUrl\":\"https:\\\/\\\/5mn.ch\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/5mn-icon-512_1.png\",\"width\":512,\"height\":512,\"caption\":\"5mn\"},\"image\":{\"@id\":\"https:\\\/\\\/5mn.ch\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Insights - 5mn","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/5mn.ch\/de\/insights\/","og_locale":"de_DE","og_type":"article","og_title":"Insights - 5mn","og_description":"Your Daily Brief Swiss and European biotech news, every weekday.","og_url":"https:\/\/5mn.ch\/de\/insights\/","og_site_name":"5mn","article_modified_time":"2026-10-12T10:46:05+00:00","twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/5mn.ch\/insights\/","url":"https:\/\/5mn.ch\/insights\/","name":"Insights - 5mn","isPartOf":{"@id":"https:\/\/5mn.ch\/#website"},"datePublished":"2025-04-14T14:43:26+00:00","dateModified":"2026-10-12T10:46:05+00:00","breadcrumb":{"@id":"https:\/\/5mn.ch\/insights\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/5mn.ch\/insights\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/5mn.ch\/insights\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"http:\/\/5mn.ch\/"},{"@type":"ListItem","position":2,"name":"Insights"}]},{"@type":"WebSite","@id":"https:\/\/5mn.ch\/#website","url":"https:\/\/5mn.ch\/","name":"5mn","description":"","publisher":{"@id":"https:\/\/5mn.ch\/#organization"},"alternateName":"5mn.ch","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/5mn.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/5mn.ch\/#organization","name":"5mn","alternateName":"5mn.ch","url":"https:\/\/5mn.ch\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/5mn.ch\/#\/schema\/logo\/image\/","url":"https:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/5mn-icon-512_1.png","contentUrl":"https:\/\/5mn.ch\/wp-content\/uploads\/2026\/10\/5mn-icon-512_1.png","width":512,"height":512,"caption":"5mn"},"image":{"@id":"https:\/\/5mn.ch\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"http:\/\/5mn.ch\/de\/wp-json\/wp\/v2\/pages\/16","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/5mn.ch\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/5mn.ch\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/5mn.ch\/de\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/5mn.ch\/de\/wp-json\/wp\/v2\/comments?post=16"}],"version-history":[{"count":21,"href":"http:\/\/5mn.ch\/de\/wp-json\/wp\/v2\/pages\/16\/revisions"}],"predecessor-version":[{"id":1598,"href":"http:\/\/5mn.ch\/de\/wp-json\/wp\/v2\/pages\/16\/revisions\/1598"}],"wp:attachment":[{"href":"http:\/\/5mn.ch\/de\/wp-json\/wp\/v2\/media?parent=16"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}